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1183-67 Alteration of L-Type Calcium Currents in Human 
Cardiopathy 
Florence Leclercq, Sthphanie Barrere-Lemarre, Christophe Piot, Jean-Marc Frapie, Joel 
Nargeot. Sylvain Richard, Human Genetic Institute. Montpellier, France, Amaud de 
Villeneuve Hospital, Montpellier, France 
Background. There are controversies concerning calcium currents changes associated 
with different stages of cardiopathy (compensated hypertrophy or heart failure). 
Methods. Human myocytes (n=160) were obtained from right atrial appendages during 
open-heart surgery in 40 patients (pts) with acute (groupA) or chronic (group B) cardiop- 
athy. Group A included pts with recent (less than one month) mitral regurgitation (MR) 
linked to chordal tendinee rupture (3 pts, n=13); group B included pts with chronic MR (6 
pts, n=21). aortic stenosis (5 pts, n=16), aortic regurgitation (6 pts, n=32), ischemic cardi- 
opathy (20 pts, n=78). Calcium current ICaL was recorded from freshly dissociated myo- 
cytes with the whole-cell patch-clamp technique. Cell capacitance (picofarad: pf), ICaL 
peak amplitude (picoampere: PA), and ICaL density (pA/pF) were measured. Left vsntric- 
ular (LV) dilatation and/or hypertrophy (echocardiography). LV ejection fraction (angio- 
graphic determination), NYHA functional class, age and therapy were taken into account. 
Results. In group A, ICaL peak amplitude was 490+/-60pA, ICaL density was 6.5 +/-0.8 
pA/pF, and cell capacitance was 76+/-15 pF. In comparison, group B was characterized 
by highly significant reduction of both ICaL peak and density (220+/-l 5 pA and 1.7 +I-2 
pA/pF; pcO.0001) and by a twofold increase of cell capacitance (142+/-55 pF; p<O.OOl). 
In group B. cell capacitance was markedly larger in advanced (LVEF<35%) ischemic car- 
diopathy (178+/-13 pF; p<O.Ol) whereas a dramatic decrease of peak current was asso- 
ciated with chronic MR (98+1-34 pA; p-zO.001). LVEF and NYHA class were not predictive 
of ICaL peak amplitude. Calcium channel antagonists and/or B-blockers therapy had no 
significant effect on current whereas age > 70 years and LV dilatation were significantly 
related to reduced ICaL density (pcO.01). 
Conclusion. There is a reduction of ICaL peak density associated with chronic cardiopa- 
thy in human. However, decrease in peak ICaL amplitude and/or increase in cell capaci- 
tance may have variable contribution in different diseases. Alteration of calcium currents 
in right atrial myocytes may reflect involvement of hemodynamic, neurohormonal or sys- 
temic factors. 
all (n=7) and from LV of 6 normal (NL) dogs. Using specific primers in reverse tren- 
SCriptSSS-pOlynWSSS chain reaction, BNP and ANP were identified on agarose-ethidium 
gel; corresponding fluorescent bands were quantified in densitometric units and normal- 
ized to glyceraldehyde-3 phosphate dehydrogenase (GAPDH), a housekeeping gene. 
Results: The results are shown in the table. Exoression of both BNP and ANP increased 
in untreated HF dogs compared to NL. Treatment with ER-MET reduced mRNA expres- 
sion of both BNP and ANP when cornoared to untreated HF doos. Conclusions: The 
findings Indicate that in dogs with HF, monotherapy with ER-MET reduces mRNA 
expression of both BNP and ANP. These findings are consistent with the observed 
reduction in mortality and morbidity in patients with HF. 
NL HF-Untreated 
BNP/GAPDH 0.54 + 0.02 1.60+0.10’ 0.64 + 0.07’* 
ANP/GAPDH 0.48 -+ 0.05 1.32+0.03’ 0.82 f. 0.03”’ 
‘=P<O.O5 vs. NL; “=P<O.O5 vs. HF-Untreated 
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1183-68 Pur fl, a Single Stranded DNA Binding Protein 
Represses SRF Mediated Muscle Gene Expression: 
Implications in Impaired Cardiac Muscle Gene 
Expression During Heart Failure 
Madhu Gupta, Vithida Sueblinvong, Mahesh P. Gupta, The Heart Institute for Children, 
Hope Childrens Hospital, Oak Lawn, IL, The University of Chicago, Chicago, IL 
Background: Pur proteins play a role in cell growth and differentiation by modulating cell 
cycle progression, replication and transcription of certain genes including smooth muscle 
actin. We have previously identified a strong negative regulatory element (PNR) at +66 to 
+108 bp region of cardiac aMHC gene. PNR collaborated with positive regulatory factors 
a interacting within the -200 bp promoter region of this gene, encompassing SREs 
(serum response elements). We subsequently cloned one of the transcription factors 
binding to PNR as Purp. This study examined the role of PurP in SRF mediated activation 
of a-MHC gene promoter. 
Methods: Transient transfection assays in primary cultures of cardiomyocytes analyzed 
the effect of SRF or Purp, alone or in combination on a-MHC promoter activity using 
luciferase as reporter. Gel -shift assay analyzed DNA-protein interaction. 
Results: Transfection of SRF cDNA activateda-MHC promoter/luciferase activity by 3 to 
5 fold. Inclusion of Puti exoression vector reduced SRF mediated activation bv 1 to 2. 
fold. Purp alone caused 40% repression of basal activity of a-MHC gene promoter. Gel- 
shift assay usino cardiac and Sol8 nuclear extracts and SRE of a-MHC demonstrated 
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two DNA-nuclear protein complexes, upper complex (UC) and lower (LC) complex. 
Super shift assay using specific antibody against Purp established LC as Purp. The 
specificity of this interaction in cardiac nuclear extract was examined further by using 
SREs of various muscle genes and of c-fos gene. Muscle SREs produced UC and LC 
whereas c-fos SRE produced only UC. Purified GST- Pulp protein showed sequence 
specific interaction with three different SREs of muscle genes but none with c-fos SRE. 
Competitive binding was observed between in vitro synthesized SRF and GST- PurPfor 
muscle SRE. Western blot and Northern blot analysis showed 3-fold induction in PurP 
expression in rat hearts subjected to pressure load with 70% decrease in a-MHC mRNA 
was observed. 
Conclusion: Purbthrough its interaction with SRE represses SRF mediated activation of 
a-MHC gene expression. Increased level of this protein in pressure load hypertrophy 
suggest its involvement in reducing the mRNA level of a-MHC. 
1183-69 Chronic Monotherapy With Extended Release 
Metoprolol Succinate Attenuates mRNA Gene 
Expression of Brain and Atrial Natriuretic Peptides in 
Left Ventricular Myocardium of Dogs With Heart Failure 
Sharad Rastoai, Ramesh C. Gupta, Sudhish Mishra, Hideaki Morita, George Suzuki, 
Sidney Goldstein, Hani N. Sabbah. Henry Ford Health System, Detroit, Ml 
Background: Plasma levels of brain (BNP) and atrial (ANP) natriuretic peptides are 
increased in heart failure (HF) and are predictive of poor outcome. Therapy with 
extended release metoprolol succinate (ER-MET) was shown to reduce mortality and 
morbidity in patients with HF. We previously showed that monotherapy with ER-MET 
increases LV ejection fraction and attenuates LV remodeling in dogs with chronic HF. In 
the this study, we examined the effects of ER-MET, a selective p, -receptor antagonist, 
on mRNA gene expression of BNP and ANP in LV of dogs with microembolization- 
induced HF. Methods: Total RNA was isolated from LV tissue of 14 dogs with HF ran- 
domized to 3 months therapy with ER-MET (50 mg, once daily, n=7) or to no therapy at 
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HF + ER-MET 
Michel Komaida, Hugo Madeira, Kristian Thygssen. Marco Bobbio, Wybren Jaarsma, 
Guenther Riegger, Jordi Soler-Soler. Lars Ryden, Per Hildebrandt, Beatrix Lutiger, 
Willem Remme, on behalf of the CARMEN investigators, Pitie Salpetriers Hospital, Paris, 
France, STICARES Cardiovascular Research Foundation, Rhoon. The Netherlands 
Background: Although current treatment guidelines for chronic heart failure (CHF) rec- 
ommend ACE-I and eblockers, P-blockers are still grossly underused. Their historical 
contra-indication and the perception of a difficult up-titration might have added to the 
slow uptake of P-blockers despite their proven reduction of mortality and morbidity in 
CHF patients. The aims of the CARMEN study were to compare the effects on cardiac 
remodeling, safety and tolerability of the ACE-I Enalapril (E) against Calvedilol (C) a 
combined PI&a,- blocker. 
Methods: CARMEN is a parallel-group, 3.arm, double-dummy study conducted I” 13 
European countries. Patients were randomized to C&E, C or E treatment arms, uptitrated 
on C to 25mg (50mg in patients 2 85kg) bid target dose and/or E to 1Omg bid target 
dose, and continued for 18 months. In the C&E arm, C was uptitrated first. Effects on left 
ventricular (LV) remodeling were assessed by echocardiography at baseline, months 
6.12 and 18. Hospitalizations and deaths were adjudicated by a blinded endpoint com- 
mittee. 
Results: The safety population included 572 mild CHF patients (C&E = 191; C = 191; E 
= 190). Mean age was 62 years, with 81% male. 65% were treated with an ACE-I 
whereas only 6% received a bblocker prior to study start. LV end systolic volume index 
was reduced in both C&E and C groups, but not in E. Similar percentages of patients 
were withdrawn 31%, 30% and 30%. experienced serious adverse events (AE) 28%. 
29% and 34% and any AE 79% (497 AE), 77% (426 AE) and 75% (461 AE) in the C&E, 
C and E arm. respectively. The number of deaths was equal in all groups (N=14) with 6, 
9 and 10 cardiovascular deaths in the C&E, C and E arm, respectively. All-cause and 
cardiovascular hospitalizations occurred in 26%. 27% and 32% and in 8%, 10% and 15% 
of patients in the C&E, C and E arms, respectively. Notably, there was no difference in 
AE during uptitration. 
Conclusion: All three treatment arms showed a very similar safety profile. In contrast to 
common perception, there was no difference in tolerability between an ACE-I and C. This 
result is even more remarkable as the high prestudy use of ACE-I might have introduced 
a bias by selecting ACE-I tolerant patients, who were only switched from their former 
ACE-I to E. 
1184-71 Predictors of p-blocker Utilization in Managed Care 
Patients With Heart Failure 
Carla A. Sueta, David W. Brown, Jill McCardle, Alain Bertoni, David Gaff. Medical 
Review of North Carolina, Gary, NC, Wake Forest University, Winston-Salem, NC 
Background: Heart failure(HF) is an increaslng cause of mortality and morbidity. 
Despite clinical trials and evidence-based guidelines that recommend P-blockers in 
patients with systolic dysfunction, utilization is low. The North Carolina Achieving Cardiac 
Excellence Project is designed to increase the utilization of angiotensin converting 
enzyme inhibitor(ACE-I) and P-blocker therapies in managed care patients(pts) with sys- 
tolic HF. The purpose of this study is to determlne the predictors of Pblocker prescription 
at baseline. 
Methods: Data obtained from outpatient medical record abstraction were available for 
1501 pts treated for HF in 2000. Pts on dialysis or with contraindications to p-blockers 
